Alpelisib in combination with olaparib is in clinical development for the treatment of adults with platinum-resistant or refractory, high-grade serous/endometrioid ovarian cancer, including fallopian tube cancer or primary peritoneal cancer. These cancers occur in the female reproductive system and are often grouped together as they are treated in the same way. Tumours can occur in the ovaries, fallopian tubes or peritoneum. Serous ovarian cancer is the most common subtype. Platinum-refractory refers to progression of disease while receiving the latest line of platinum-based chemotherapy or within 4 weeks of last dose. Platinum-resistant refers to progression within one to six months after completing platinum-based therapy.
Alpelisib and Olaparib for treating platinum-resistant or refractory BRCA wild-type ovarian cancer
Alpelisib in combination with olaparib is in clinical development for the treatment of adults with platinum-resistant or refractory, high-grade serous/endometrioid ovarian cancer, including fallopian tube cancer or primary peritoneal cancer.